AP2003002734A0 - Purification of HBV antigens for use in vaccines. - Google Patents

Purification of HBV antigens for use in vaccines.

Info

Publication number
AP2003002734A0
AP2003002734A0 APAP/P/2003/002734A AP2003002734A AP2003002734A0 AP 2003002734 A0 AP2003002734 A0 AP 2003002734A0 AP 2003002734 A AP2003002734 A AP 2003002734A AP 2003002734 A0 AP2003002734 A0 AP 2003002734A0
Authority
AP
ARIPO
Prior art keywords
vaccines
purification
hbv antigens
antigens
antigen
Prior art date
Application number
APAP/P/2003/002734A
Other languages
English (en)
Inventor
Heyder Koen De
Peter Schu
Michelle Serantoni
Opstal Omer Van
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0019728.5A external-priority patent/GB0019728D0/en
Priority claimed from GB0101334A external-priority patent/GB0101334D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AP2003002734A0 publication Critical patent/AP2003002734A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
APAP/P/2003/002734A 2000-08-10 2001-08-07 Purification of HBV antigens for use in vaccines. AP2003002734A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds
PCT/EP2001/009100 WO2002012287A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines

Publications (1)

Publication Number Publication Date
AP2003002734A0 true AP2003002734A0 (en) 2003-03-31

Family

ID=26244821

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2003/002734A AP2003002734A0 (en) 2000-08-10 2001-08-07 Purification of HBV antigens for use in vaccines.

Country Status (35)

Country Link
US (3) US20030235590A1 (enExample)
EP (2) EP1666487B1 (enExample)
JP (2) JP2004505992A (enExample)
KR (1) KR100804922B1 (enExample)
CN (1) CN1468256B (enExample)
AP (1) AP2003002734A0 (enExample)
AR (1) AR030325A1 (enExample)
AT (2) ATE313558T1 (enExample)
AU (2) AU2001282073B2 (enExample)
BG (1) BG66038B1 (enExample)
BR (1) BRPI0113155C1 (enExample)
CA (2) CA2740282A1 (enExample)
CY (2) CY1106310T1 (enExample)
CZ (1) CZ303217B6 (enExample)
DE (2) DE60136400D1 (enExample)
DK (2) DK1666487T3 (enExample)
DZ (1) DZ3470A1 (enExample)
EA (1) EA006433B1 (enExample)
EG (1) EG25829A (enExample)
ES (2) ES2254464T3 (enExample)
HU (1) HU228932B1 (enExample)
IL (2) IL154301A0 (enExample)
MX (1) MXPA03001235A (enExample)
MY (1) MY128999A (enExample)
NO (1) NO20030635L (enExample)
NZ (1) NZ524012A (enExample)
OA (1) OA12361A (enExample)
PE (1) PE20020287A1 (enExample)
PL (1) PL204736B1 (enExample)
PT (1) PT1666487E (enExample)
SI (2) SI1666487T1 (enExample)
SK (2) SK288079B6 (enExample)
UA (1) UA79735C2 (enExample)
UY (1) UY26882A1 (enExample)
WO (1) WO2002012287A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
DK1909830T3 (da) * 2005-08-02 2011-12-19 Novartis Vaccines & Diagnostic Formindskelse af interferens mellem olieholdige adjuvanser og antigener indeholdende overfladeaktivt middel
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
CN103357003A (zh) 2006-09-07 2013-10-23 葛兰素史密丝克莱恩生物有限公司 疫苗
US20100074918A1 (en) 2007-05-02 2010-03-25 Jan Poolman Vaccine
US8436514B2 (en) * 2007-10-30 2013-05-07 Kyocera Corporation Acoustic wave device comprising an inter-digital transducer electrode
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
BRPI1012078A2 (pt) * 2009-05-27 2019-09-24 Glaxosmithkline Biologicals Sa construto de proteína, composição imunogênica, molécula de ácido nucleico , métodos de induzir uma resposta imune a casb7439 e de tratar um animal humano ou não-humano, e, uso de uma composição imunogênica
WO2012095834A1 (en) * 2011-01-14 2012-07-19 Hal Allergy Holding B.V. Immunoassay for direct determination of antigen content of products comprising adjuvant-coupled-antigen particles
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
JP7404226B2 (ja) 2017-07-18 2023-12-25 セラム インスティテュート オブ インディア プライベート リミティド 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
JP7779838B2 (ja) * 2019-12-13 2025-12-03 遠大賽威信生命科学（南京）有限公司 免疫刺激性組成物及びその用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
KR850001534A (ko) 1983-08-22 1985-03-30 제임스 에프. 나우톤 형질전환된 효모로 부터 유도된 면역원성 HBsAg
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
EP0314240A3 (en) * 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
JPH06503821A (ja) 1990-12-20 1994-04-28 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） Ｂ型肝炎表面抗原に基づくワクチン
JP3026029B2 (ja) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
AU657168B2 (en) 1991-09-18 1995-03-02 Amgen, Inc. Hepatitis B vaccine with bile salt adjuvant
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
DE69535530D1 (de) * 1994-10-24 2007-08-16 Ophidian Pharm Inc Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR20010041629A (ko) * 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
CA2355680A1 (en) * 1998-12-23 2000-06-29 Qinjian Zhao Improved recombinant hepatitis b surface antigen
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах

Also Published As

Publication number Publication date
AR030325A1 (es) 2003-08-20
DE60116107T2 (de) 2006-08-03
UY26882A1 (es) 2002-03-22
JP2004505992A (ja) 2004-02-26
BRPI0113155C1 (pt) 2021-05-25
SK1692003A3 (en) 2003-08-05
SI1307473T1 (sl) 2006-04-30
PT1666487E (pt) 2008-12-26
OA12361A (en) 2004-04-13
US20060159705A1 (en) 2006-07-20
CY1108789T1 (el) 2014-04-09
HUP0302951A2 (hu) 2003-12-29
KR20030029127A (ko) 2003-04-11
SI1666487T1 (sl) 2009-02-28
EA200300129A1 (ru) 2003-10-30
AU8207301A (en) 2002-02-18
ES2314555T3 (es) 2009-03-16
WO2002012287A1 (en) 2002-02-14
PE20020287A1 (es) 2002-06-20
BG66038B1 (bg) 2010-11-30
IL154301A0 (en) 2003-09-17
EP1307473B1 (en) 2005-12-21
UA79735C2 (uk) 2007-07-25
HUP0302951A3 (en) 2004-10-28
BR0113155A (pt) 2003-07-08
PL204736B1 (pl) 2010-02-26
IL154301A (en) 2009-11-18
EP1666487B1 (en) 2008-10-29
NZ524012A (en) 2004-02-27
EG25829A (en) 2012-09-02
ES2254464T3 (es) 2006-06-16
PL362322A1 (en) 2004-10-18
EP1666487A1 (en) 2006-06-07
AU2001282073B2 (en) 2005-01-20
JP2012255015A (ja) 2012-12-27
DZ3470A1 (fr) 2002-02-14
BRPI0113155B8 (pt) 2019-08-13
CZ303217B6 (cs) 2012-05-30
SK288079B6 (sk) 2013-06-03
JP5559847B2 (ja) 2014-07-23
DE60116107D1 (de) 2006-01-26
NO20030635L (no) 2003-04-01
MXPA03001235A (es) 2004-07-16
NO20030635D0 (no) 2003-02-07
MY128999A (en) 2007-03-30
DK1307473T3 (da) 2006-05-01
DK1666487T3 (da) 2009-01-12
BRPI0113155B1 (pt) 2018-11-21
CN1468256A (zh) 2004-01-14
DE60136400D1 (de) 2008-12-11
HK1056884A1 (en) 2004-03-05
CA2427475C (en) 2011-07-05
KR100804922B1 (ko) 2008-02-20
ATE313558T1 (de) 2006-01-15
EP1307473A1 (en) 2003-05-07
US8624004B2 (en) 2014-01-07
HU228932B1 (en) 2013-06-28
CA2427475A1 (en) 2002-02-11
CZ2003385A3 (cs) 2003-06-18
US20030235590A1 (en) 2003-12-25
CA2740282A1 (en) 2002-02-11
BG107545A (bg) 2004-01-30
US20090123496A1 (en) 2009-05-14
CN1468256B (zh) 2010-10-27
EA006433B1 (ru) 2005-12-29
CY1106310T1 (el) 2011-10-12
ATE412665T1 (de) 2008-11-15
SK288069B6 (sk) 2013-05-03

Similar Documents

Publication Publication Date Title
AP2003002734A0 (en) Purification of HBV antigens for use in vaccines.
AU6616301A (en) Modification of hepatitis b core antigen
ATE542829T1 (de) Impfstoff
EP1504112A4 (en) DEVELOPMENT OF PREVENTIVE VACCINE AGAINST FILOVIRUS INFECTION IN PRIMATES
WO2004030608A3 (en) Nanoemulsion vaccines
GB0014907D0 (en) Antigenic polypeptides
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
UA85536C2 (en) Viral antigens
WO2003066094A3 (en) Hepatitis b vaccines
EP1337149A4 (en) VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
AU2003261977A1 (en) Hbv precore protein capable of forming particles
EE200200157A (et) Vaktsiin
ATE552264T1 (de) Neue oberflächenprotein- (hbsag-) variante des hepatitis b virus
WO2002032455A3 (en) Vaccine
ECSP034474A (es) Nuevo tratamiento
AU2002219290A1 (en) Proteinic antigens inducing antibodies neutralising hiv virus
DE60013242D1 (de) Impfungsmethode zur effizienten induktion der t-lymphozyten zytotoxischantwort
SI1436397T1 (sl) Cepivo proti virusu hepatitisa C
TW200510545A (en) HBV pre-core protein having particle-forming ability